alexa Anti-IgE Therapy

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Anti-IgE Therapy

A monoclonal antibody that blocks IgE (omalizumab) is now used in the treatment of selected patients with severe asthma. It is expensive, so patients must be selected carefully for a trial of therapy.

More potent anti-IgE antibodies that may have a broader spectrum of effects are in development.

Allergens bind to a low-affinity IgE receptor (FcεRII, CD23) as well as the high-affinity receptor FcεRI on several immune cells, including T- and B-lymphocytes. An anti-CD23 antibody (lumiliximab) is well tolerated and reduces IgE concentrations in patients with mild asthma, but its clinical efficacy has not been reported.

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger